drugset / Trial / NCT01302951

Penetration of Moxifloxacin Into Liver Tissue of Patients Undergoing Liver Resection.

NCT01302951

Phase 4 Completed 34 enrolled University Hospital, Saarland Bayer · collab
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The aim of the study is to provide data on the pharmacokinetics (PK) of moxifloxacin (MXF) in serum and liver tissue of patients undergoing liver resection due to primary or secondary tumor of the liver.

Timeline

Start
2008-07
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Moxifloxacin Small molecule 400 mg Intravenous